Cargando…

Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer

BACKGROUND: The mutational profile of oncogenic driver genes play an important role in non-small-cell lung cancer (NSCLC). The need of a testing panel capable of comprehensively determining patient genotypes in limited amounts of material has increased since the recent association of nine core oncog...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuo, Qu, Xiujuan, Cao, Lili, Hu, Xuejun, Hou, Kezuo, Liu, Yunpeng, Che, Xiaofang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269179/
https://www.ncbi.nlm.nih.gov/pubmed/32581578
http://dx.doi.org/10.2147/CMAR.S250822
_version_ 1783541734750289920
author Wang, Shuo
Qu, Xiujuan
Cao, Lili
Hu, Xuejun
Hou, Kezuo
Liu, Yunpeng
Che, Xiaofang
author_facet Wang, Shuo
Qu, Xiujuan
Cao, Lili
Hu, Xuejun
Hou, Kezuo
Liu, Yunpeng
Che, Xiaofang
author_sort Wang, Shuo
collection PubMed
description BACKGROUND: The mutational profile of oncogenic driver genes play an important role in non-small-cell lung cancer (NSCLC). The need of a testing panel capable of comprehensively determining patient genotypes in limited amounts of material has increased since the recent association of nine core oncogenic driver genes as tumor predictive biomarkers. METHODS: Surgically resected samples from 214 NSCLC patients (168 patients with adenocarcinomas and 46 with squamous cell cancers) were included. A multiplexed PCR-based assay was developed to simultaneously test 118 hotspot mutations and fusions in nine driver genes. RESULTS: The sensitivity of the kit was 1% for gene mutation and 450 copies for gene fusion. Genetic alterations were detected in 143 (66.8%) patients by the assay. The three most common alterations identified were EGFR mutations (50.9%), KRAS mutations (8.4%) and ALK fusions (4.7%). Eight (3.7%) patients harbored concurrent mutations, and the most common partners were EGFR mutations which were observed in the eight patients. No associations between survival and EGFR, KRAS, and ALK status were observed. Patients with two or more alterations exhibited shorter DFS compared to those with single mutations (P=0.032), whilst had no significant difference in OS (P=0.245). However, only TNM stage was an independent predictor of OS (HR=2.905, P<0.001) as well as DFS (HR=2.114, P<0.001) in our cohort in multivariate analysis. Furthermore, patients with the L858R mutation had longer DFS (P=0.014) compared to other sensitizing mutations and tended to have better OS but the differences were not significant (P=0.06). CONCLUSION: These findings suggest this multiplex gene panel testing technique can be efficiently used to detect nine driver genes in a limited number of specimens. This methodology would have the potential to save both specimens and time compared to the combination of all assays by other methods.
format Online
Article
Text
id pubmed-7269179
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72691792020-06-23 Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer Wang, Shuo Qu, Xiujuan Cao, Lili Hu, Xuejun Hou, Kezuo Liu, Yunpeng Che, Xiaofang Cancer Manag Res Original Research BACKGROUND: The mutational profile of oncogenic driver genes play an important role in non-small-cell lung cancer (NSCLC). The need of a testing panel capable of comprehensively determining patient genotypes in limited amounts of material has increased since the recent association of nine core oncogenic driver genes as tumor predictive biomarkers. METHODS: Surgically resected samples from 214 NSCLC patients (168 patients with adenocarcinomas and 46 with squamous cell cancers) were included. A multiplexed PCR-based assay was developed to simultaneously test 118 hotspot mutations and fusions in nine driver genes. RESULTS: The sensitivity of the kit was 1% for gene mutation and 450 copies for gene fusion. Genetic alterations were detected in 143 (66.8%) patients by the assay. The three most common alterations identified were EGFR mutations (50.9%), KRAS mutations (8.4%) and ALK fusions (4.7%). Eight (3.7%) patients harbored concurrent mutations, and the most common partners were EGFR mutations which were observed in the eight patients. No associations between survival and EGFR, KRAS, and ALK status were observed. Patients with two or more alterations exhibited shorter DFS compared to those with single mutations (P=0.032), whilst had no significant difference in OS (P=0.245). However, only TNM stage was an independent predictor of OS (HR=2.905, P<0.001) as well as DFS (HR=2.114, P<0.001) in our cohort in multivariate analysis. Furthermore, patients with the L858R mutation had longer DFS (P=0.014) compared to other sensitizing mutations and tended to have better OS but the differences were not significant (P=0.06). CONCLUSION: These findings suggest this multiplex gene panel testing technique can be efficiently used to detect nine driver genes in a limited number of specimens. This methodology would have the potential to save both specimens and time compared to the combination of all assays by other methods. Dove 2020-05-28 /pmc/articles/PMC7269179/ /pubmed/32581578 http://dx.doi.org/10.2147/CMAR.S250822 Text en © 2020 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Shuo
Qu, Xiujuan
Cao, Lili
Hu, Xuejun
Hou, Kezuo
Liu, Yunpeng
Che, Xiaofang
Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer
title Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer
title_full Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer
title_fullStr Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer
title_full_unstemmed Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer
title_short Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer
title_sort assessment of nine driver gene mutations in surgically resected samples from patients with non-small-cell lung cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269179/
https://www.ncbi.nlm.nih.gov/pubmed/32581578
http://dx.doi.org/10.2147/CMAR.S250822
work_keys_str_mv AT wangshuo assessmentofninedrivergenemutationsinsurgicallyresectedsamplesfrompatientswithnonsmallcelllungcancer
AT quxiujuan assessmentofninedrivergenemutationsinsurgicallyresectedsamplesfrompatientswithnonsmallcelllungcancer
AT caolili assessmentofninedrivergenemutationsinsurgicallyresectedsamplesfrompatientswithnonsmallcelllungcancer
AT huxuejun assessmentofninedrivergenemutationsinsurgicallyresectedsamplesfrompatientswithnonsmallcelllungcancer
AT houkezuo assessmentofninedrivergenemutationsinsurgicallyresectedsamplesfrompatientswithnonsmallcelllungcancer
AT liuyunpeng assessmentofninedrivergenemutationsinsurgicallyresectedsamplesfrompatientswithnonsmallcelllungcancer
AT chexiaofang assessmentofninedrivergenemutationsinsurgicallyresectedsamplesfrompatientswithnonsmallcelllungcancer